Dormann D, Ebner C, Jarman E R, Montermann E, Kraft D, Reske-Kunz A B
Clinical Research Unit, Department of Dermatology, University of Mainz, Mainz, Germany.
Clin Exp Allergy. 1998 Nov;28(11):1374-83. doi: 10.1046/j.1365-2222.1998.00407.x.
Allergoids are widely used in specific immunotherapy for the treatment of IgE-mediated allergic diseases.
The aim of this study was to analyse whether a modification of birch pollen allergens with formaldehyde affects the availability of T-cell epitopes.
Efficient modification of the allergens was verified by determining IgE and IgG binding activity using ELISA inhibition tests. T-cell responses to birch pollen allergoids were analysed in polyclonal systems, using peripheral blood mononuclear cells (PBMC) of five birch pollen-allergic individuals, as well as birch pollen extract-reactive T-cell lines (TCL), established from the peripheral blood of 14 birch pollen-allergic donors. To determine whether the modification of natural (n)Bet v 1 with formaldehyde or maleic anhydride results in epitope-specific changes in T-cell reactivities, 22 Bet v 1-specific T-cell clones (TCC), established from nine additional birch pollen-allergic individuals, were tested for their reactivity with these products.
The majority of PBMC and TCL showed a reduced response to the birch pollen extract allergoid. Bet v 1-specific TCC could be divided into allergoid-reactive and -non-reactive TCC. No simple correlation between possible modification sites of formaldehyde in the respective T-cell epitopes and the stimulatory potential of the allergoid was observed. Mechanisms of suppression or of anergy induction were excluded as an explanation for the non-reactivity of representative TCC. All TCC could be stimulated by maleylated and unmodified nBet v 1 to a similar extent.
These results demonstrate differences in the availability of T-cell epitopes between allergoids and unmodified allergens, which are most likely due to structural changes within the allergen molecule.
变应原类制剂广泛用于特异性免疫治疗,以治疗IgE介导的过敏性疾病。
本研究旨在分析用甲醛修饰桦树花粉变应原是否会影响T细胞表位的可及性。
通过酶联免疫吸附抑制试验测定IgE和IgG结合活性,验证变应原的有效修饰。在多克隆系统中,使用5名桦树花粉过敏个体的外周血单核细胞(PBMC)以及从14名桦树花粉过敏供体的外周血中建立的桦树花粉提取物反应性T细胞系(TCL),分析对桦树花粉变应原类制剂的T细胞反应。为了确定用甲醛或马来酸酐对天然(n)Bet v 1进行修饰是否会导致T细胞反应性发生表位特异性变化,对从另外9名桦树花粉过敏个体中建立的22个Bet v 1特异性T细胞克隆(TCC)与这些产物的反应性进行了检测。
大多数PBMC和TCL对桦树花粉提取物变应原类制剂的反应降低。Bet v 1特异性TCC可分为对变应原类制剂有反应和无反应的TCC。未观察到各自T细胞表位中甲醛可能的修饰位点与变应原类制剂的刺激潜力之间存在简单的相关性。排除了抑制或无反应性诱导机制作为代表性TCC无反应性的解释。所有TCC对马来酰化和未修饰的nBet v 1的刺激程度相似。
这些结果表明变应原类制剂与未修饰的变应原之间T细胞表位的可及性存在差异,这很可能是由于变应原分子内的结构变化所致。